{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:58:53Z","timestamp":1791248333184,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer (Schweiz) AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40123-026-01320-5","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:35:27Z","timestamp":1769718927000},"page":"831-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Outcomes of Intravitreal Aflibercept 8\u00a0mg in Eyes Previously Treated with Aflibercept 2\u00a0mg for Neovascular Age-Related Macular Degeneration with AI-Based Biomarker Quantification"],"prefix":"10.1007","volume":"15","author":[{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos Kitsos","family":"Kalyvianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannic Pannatier","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Gallo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Crozat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Path\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3400","authenticated-orcid":false,"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"9652","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(08)61759-6","volume":"372","author":"HR Coleman","year":"2008","unstructured":"Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet. 2008;372(9652):1835\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(08)61759-6.","journal-title":"Lancet"},{"issue":"12","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124(12):1753\u201363. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035.","journal-title":"Ophthalmology"},{"key":"1320_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70113-X","author":"RRA Bourne","year":"2013","unstructured":"Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013. https:\/\/doi.org\/10.1016\/S2214-109X(13)70113-X.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"1320_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/AOS.12463","volume":"92","author":"GK Broadhead","year":"2014","unstructured":"Broadhead GK, Hong T, Chang AA. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92(8):713\u201323. https:\/\/doi.org\/10.1111\/AOS.12463.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1320_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):1\u201317. https:\/\/doi.org\/10.1186\/S12967-023-03937-7.","journal-title":"J Transl Med"},{"key":"1320_CR6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S97653","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367. https:\/\/doi.org\/10.2147\/DDDT.S97653.","journal-title":"Drug Des Devel Ther"},{"issue":"0","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.ORET.2025.01.010\/ATTACHMENT\/71D8D26D-6E43-483B-AEAB-26ABE97D9B02\/MMC14.PDF","volume":"0","author":"DWT Yap","year":"2025","unstructured":"Yap DWT, Tan BKJ, Chong KTY, Wong TY, Cheung CMG. Persistence of retinal fluid after anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Retina. 2025;0(0):1\u201315. https:\/\/doi.org\/10.1016\/J.ORET.2025.01.010\/ATTACHMENT\/71D8D26D-6E43-483B-AEAB-26ABE97D9B02\/MMC14.PDF.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","volume":"181","author":"LA Kim","year":"2012","unstructured":"Kim LA, D\u2019Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376\u20139. https:\/\/doi.org\/10.1016\/j.ajpath.2012.06.006.","journal-title":"Am J Pathol"},{"issue":"6","key":"1320_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/EYE.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29(6):721\u201331. https:\/\/doi.org\/10.1038\/EYE.2015.48.","journal-title":"Eye"},{"issue":"1","key":"1320_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration \u2013 a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20(1):294. https:\/\/doi.org\/10.1186\/S12886-020-01554-2.","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"1320_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/S12325-019-00971-0","volume":"36","author":"T Empeslidis","year":"2019","unstructured":"Empeslidis T, Storey M, Giannopoulos T, et al. How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv Ther. 2019;36(7):1532. https:\/\/doi.org\/10.1007\/S12325-019-00971-0.","journal-title":"Adv Ther"},{"issue":"5","key":"1320_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15051416","volume":"15","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Di Bin F, Lanzetta P. Pharmacokinetic and pharmacodynamic rationale for extending VEGF inhibition increasing intravitreal aflibercept dose. Pharmaceutics. 2023;15(5):1416. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15051416.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1320_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPHTH-2024-001967","volume":"10","author":"DT Wong","year":"2025","unstructured":"Wong DT, Aboobaker S, Maberley D, Sharma S, Yoganathan P. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025;10(1):e001967. https:\/\/doi.org\/10.1136\/BMJOPHTH-2024-001967.","journal-title":"BMJ Open Ophthalmol"},{"issue":"9","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/JAMAOPHTHALMOL.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141(9):834\u201342. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2023.2421.","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"1320_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"issue":"5","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ICU.0000000000000782","volume":"32","author":"D Ferrara","year":"2021","unstructured":"Ferrara D, Newton EM, Lee AY. Artificial intelligence-based predictions in neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2021;32(5):389\u201396. https:\/\/doi.org\/10.1097\/ICU.0000000000000782.","journal-title":"Curr Opin Ophthalmol"},{"key":"1320_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.07.004","volume":"67","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovi\u0107 H. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67:1\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.07.004.","journal-title":"Prog Retin Eye Res"},{"key":"1320_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth U, Reiter GS, Riedl S, et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 2022. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100972.","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/S41433-021-01487-0","volume":"35","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Parravano M, Clemens A, et al. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye. 2021;35(8):2119\u201335. https:\/\/doi.org\/10.1038\/S41433-021-01487-0.","journal-title":"Eye"},{"issue":"2","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/BJO-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol. 2024;108(2):253\u201362. https:\/\/doi.org\/10.1136\/BJO-2022-322297.","journal-title":"Br J Ophthalmol"},{"key":"1320_CR21","doi-asserted-by":"publisher","DOI":"10.1167\/TVST.10.4.17","author":"I Mantel","year":"2021","unstructured":"Mantel I, Mosinska A, Bergin C, et al. Automated quantification of pathological fluids in neovascular age-related macular degeneration, and its repeatability using deep learning. Transl Vis Sci Technol. 2021. https:\/\/doi.org\/10.1167\/TVST.10.4.17.","journal-title":"Transl Vis Sci Technol"},{"key":"1320_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/S40123-025-01239-3","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, et al. Early outcome analysis of intravitreal aflibercept 8 mg treatment in na\u00efve patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025. https:\/\/doi.org\/10.1007\/S40123-025-01239-3.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1320_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPHTH-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10(1):2091. https:\/\/doi.org\/10.1136\/BMJOPHTH-2024-002091.","journal-title":"BMJ Open Ophthalmol"},{"issue":"6","key":"1320_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/LIFE15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F, et al. Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life. 2025;15(6):903. https:\/\/doi.org\/10.3390\/LIFE15060903.","journal-title":"Life"},{"issue":"14","key":"1320_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/JCM14144824","volume":"14","author":"C Hara","year":"2025","unstructured":"Hara C, Fujimoto S, Fukushima Y, et al. Initial response after switching to aflibercept 8 mg for neovascular age-related macular degeneration. J Clin Med. 2025;14(14):4824. https:\/\/doi.org\/10.3390\/JCM14144824.","journal-title":"J Clin Med"},{"key":"1320_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/S00417-025-06979-3","author":"K Kataoka","year":"2025","unstructured":"Kataoka K, Tanaka K, Honjyo J, et al. Treatment outcomes of switching to aflibercept 8\u00a0mg in previously-treated neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmology. 2025. https:\/\/doi.org\/10.1007\/S00417-025-06979-3.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmology"},{"issue":"18","key":"1320_CR27","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/S41433-024-03364-Y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024;38(18):3569\u201377. https:\/\/doi.org\/10.1038\/S41433-024-03364-Y.","journal-title":"Eye"},{"issue":"6","key":"1320_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537\u201344. https:\/\/doi.org\/10.1016\/j.oret.2023.11.015.","journal-title":"Ophthalmol Retina"},{"key":"1320_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.02.002","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GS, Mohan N, et al. Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina. 2025. https:\/\/doi.org\/10.1016\/j.oret.2025.02.002.","journal-title":"Ophthalmol Retina."},{"issue":"2","key":"1320_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/S41433-024-03460-Z","volume":"39","author":"S Frank-Publig","year":"2024","unstructured":"Frank-Publig S, Birner K, Riedl S, Reiter GS, Schmidt-Erfurth U. Artificial intelligence in assessing progression of age-related macular degeneration. Eye. 2024;39(2):262\u201373. https:\/\/doi.org\/10.1038\/S41433-024-03460-Z.","journal-title":"Eye"},{"key":"1320_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJO.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am J Ophthalmol. 2021;224:267. https:\/\/doi.org\/10.1016\/J.AJO.2020.12.012.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1320_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/BJO-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares V, Schmidt-Erfurth UM, Leingang O, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol. 2024;108(7):971\u20137. https:\/\/doi.org\/10.1136\/BJO-2022-323014.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1320_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/EYE.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787\u201394. https:\/\/doi.org\/10.1038\/EYE.2013.107.","journal-title":"Eye"},{"issue":"5","key":"1320_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JCM10050981","volume":"10","author":"JT Cox","year":"2021","unstructured":"Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-vegf injections. J Clin Med. 2021;10(5):1\u201316. https:\/\/doi.org\/10.3390\/JCM10050981.","journal-title":"J Clin Med"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01320-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01320-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:26:00Z","timestamp":1770902760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01320-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01320-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicol\u00f2 Bartolomeo, Konstantinos Kitsos-Kalyvianakis, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, Daniela Gallo Castro, Baptiste Crozat, Mamadou Path\u00e9 Barry, and Aude Ambresin have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study design was approved by the local ethics committee (Commission cantonale d'\u00e9thique de la recherche sur l'\u00eatre humain CER-VD -part of Swissethics) for data collection and analysis (CERVD: 2024\u201301491) and was conducted in accordance with the principles of the Helsinki Declaration and its amendments. Informed consent was collected prior to patient inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}